Jimmy Van den Eynden

20PUBLICATIONS
51CO-AUTHORS
Cellular nervous systemInnate immunityCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (20)

|Sep 30, 2024
MHC class II genotypes are independent predictors of anti-PD1 immunotherapy response in melanoma.

Arne Claeys, Jimmy Van den Eynden

|Dec 28, 2023
ALK signaling primes the DNA damage response sensitizing ALK-driven neuroblastoma to therapeutic ATR inhibition.

Marcus Borenäs, Ganesh Umapathy, Dan E Lind

Pageof 4